Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pneumococcal Vaccine, Polyvalent · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pneumococcal Vaccine, Polyvalent (23-valent) | EXPERIMENTAL | Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1. |
| Name | Type | Description |
|---|---|---|
| Pneumococcal Vaccine, Polyvalent (23-valent) | BIOLOGICAL | - |
Inclusion Criteria: * Healthy indian adults of 50 years of age * In good health; any underlying chronic illness must be documented to be in stable condition * Signed and dated informed consent prior to receipt of the study vaccine Exclusion Criteria: * Functional or anatomic asplenia * History of...
Pneumococcal Vaccine, Polyvalent is used for the prevention of pneumococcal infection. It is an investigational vaccine being studied in healthy adults aged 50 years and older to assess its safety, tolerability, and immunogenicity. The vaccine is currently in Phase 3 clinical development.
Pneumococcal Vaccine, Polyvalent is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The vaccine is being investigated for the prevention of pneumococcal infection.
Pneumococcal Vaccine, Polyvalent is in Phase 3 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in preventing pneumococcal infection.
Pneumococcal Vaccine, Polyvalent has one completed Phase 3 clinical trial, identified as NCT00496093. This trial, titled 'Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)', enrolled 133 participants aged 50 years and older to evaluate the vaccine's safety and immune response.
Yes, Pneumococcal Vaccine, Polyvalent is the same as Pneumovax 23. The clinical trial NCT00496093 refers to the vaccine as Pneumovax 23, indicating that these names are used interchangeably for the same investigational vaccine developed by Merck & Company, Inc.